Document:

amendedgenbiomicagmt

                                 GENBIOMICS, LLC
                    Investments for Pharmaceutical Research
________________________________________________________________________________

                                  ADDENDUM 1.00
                       TO THE CONTRACT BETWEEN AND AMONGST
                                 GENBIOMICS, LLC
                                       AND
                             DNAPRINT GENOMICS, INC.
                                  May 31, 2002

PURPOSE:

Both parties to the Consulting Contract "Contract" signed and executed by the
duly authorized representatives of GenBiomics, LLC and DNAPrint Genomics, Inc.
hereby agree to the following "Addendum 1.00" as an attachment to the Contract.
All terms and conditions found in "Addendum 1.00" are fully and duly accepted
and agreed to by both parties. Each party to the Contract and Addendum 1.00 have
negotiated and accepted the "Terms and Conditions" as found herein as additions
to the Contract. The Addendum 1.00 does not waive any of the existing "Contract
Terms and Conditions" as found in the Contract; as agreed to by both parties,
but both parties hereby agree that Addendum 1.00 is a valid and accepted
Addendum to The Contract, as so worded in said Contract between and amongst the
parties, GenBiomics, LLC and DNAPrint Genomics, Inc. Addendum 1.00 will be used
by both parties to help each party define its respective goals and objectives.
The budgets and payments contained herein for GenBiomics, LLC whether in cash,
options or stock are agreed to by both parties and DNAPrint Genomics, Inc.
hereby agrees to abide by the Contract Terms and Conditions as well as the
"Addendum 1.00 Terms and Conditions" as set forth herein. Both parties
furthermore agree that the Addendum 1.00 and it's language is congruous with the
language of the Consulting Contract and that neither party will exploit, nullify
or otherwise destroy in whole or in part the Consulting Contract. Any language
differences between the Addendum 1.00 and the Contract if so written and agreed
to by both parties herein; are not intended by either party to be against the
terms and conditions set forth in the Consulting Contract. Both parties hereby
agree that the language of the Consulting Contract will take precedence over any
language that is in conflict as so found by either party or their
representatives contained herein. Addendum 1.00 and all other subsequent
Addendum's to the Consulting Contract set out the work to be performed by
GenBiomics, LLC and the payments by DNAPrint Genomics, Inc. to GenBiomics, LLC
for said work performed and contained herein.

WORK TO BE PERFORMED

Task 1.0

DNAPrint Genomics, Inc. "The Client" has directed GenBiomics, LLC "The
Consultant" to assist Client in raising capital to fund its client operations
and has directed Consultant to complete the placement of funds necessary to
continue Client operations. Immediate goals and objectives include the
following:

        A.      Advise and consult on various business matters including but not
                limited to: licensing, agreements and securing additional
                intellectual properties.

        B.      Identify and secure additional sources of funds for DNAPrint
                Genomics, Inc. either equity, debt or a combination, grants,
                contracts etc. that will help the Client continue operations. The
                short range plan is to secure up to $2.0 million dollars in
                funding for the Client.

                                       1

                                 GENBIOMICS, LLC
                    Investments for Pharmaceutical Research
________________________________________________________________________________

        C.      Prepare Client for a July "Stock Holders Meeting" that will
                include a review of current operations and plans and the
                authoring of supporting documents and other support materials as
                so directed by DNAPrint Genomics, Inc. management.

        D.      Draft "Business Plan" and "Placement Memorandum" for additional
                financing.

        E.      Develop other sources of funding and prepare DNAPrint for "due
                diligence" by investors and their representatives.

        COST AND TIMING

        Task 1.0 A-E will require the efforts of 2 of GenBiomics' consultants and
        is estimated at 400 hours of consulting time and is valued at $110,000.00.
        We have used approximately 130 hours in preparing sections of the business
        plan and completing some editing of a document for a license with Penn
        State University under the direction of DNAPrint's CEO/President. We
        anticipate another 270 hours will be spent preparing drafts, reviewing
        documents and identifying additional sources of capital.

        DNAPrint and GenBiomics propose the following since DNAPrint is not able to
        pay its invoices in full at this time:

        1. DNAPrint pays consultants direct costs in cash which includes,
           travel, meals, and associated expenses.

        2. DNAPrint will pay GenBiomics, LLC a fee of 5% of the first $1.0MM
           (one million dollars) in capital raised, 4% of the second million
           dollars, ($2.0MM), 3% of the third million dollars ($3.0MM), 2%
           of the fourth million dollars ($4.0MM), 1% of the fifth million
           dollars ($5.0MM) and 1% of any additional funds above $5.0MM
           (five million dollars) in the form of options. The value of the
           options will be $0.001 per option and will be represented by a
           current stock value of $0.035 per share for DNAPrint Genomics,
           Inc. The Term of the option will be 10 years from issuance and
           the underlying shares will be represented by DNAPrint Genomics,
           Inc. fully registered and unrestricted shares and once exercised
           by GenBiomics, LLC will become immediately freely tradable. The
           strike price of these options is $0.001 per option and no further
           payments will be made for the issuance of the registered and
           unrestricted shares of DNAPrint Genomics, Inc. to GenBiomics,
           LLC.

        3. DNAPrint Genomics, Inc. will pay GenBiomics, LLC $15,000.00 in
           cash for the direct consulting work as defined in this addendum
           1.00 to the CONSULTING CONTRACT and in accordance with the terms
           and conditions of the CONSULTING CONTRACT with the balance paid
           in options at the strike price of $0.001 per share and as
           represented by the underlying current stock value agreed to by
           both parties of $0.035 per share. The option will have a life of
           10 years and will be represented by DNAPrint Genomics, Inc.
           shares that are registered and freely tradable upon exercise by
           GenBiomics, LLC as outlined in this addendum to the CONSULTING
           CONTRACT. DNAPrint Genomics, Inc. and GenBiomics, LLC will enter
           into a definitive OPTIONS AGREEMENT between and amongst the
           parties.

                                       2

                                 GENBIOMICS, LLC
                    Investments for Pharmaceutical Research
________________________________________________________________________________

        Both parties hereby agree that the work outlined and the payments received
        for work performed as defined under this Addendum 1.00 to the CONSULTING
        CONTRACT is a valid and binding addendum to the CONSULTING CONTRACT and
        that the terms and conditions as outlined herein are in compliance with the
        letter and intent and spirit of the CONSULTING CONTRACT.

        Agreed, understood and accepted:

        _______________________________                 _________________________
        GenBiomics, LLC                                 DNAPrint Genomics, Inc.

        _______________________________                 _________________________
        Date                                            Dateamendedshriveragmt

                        AMENDMENT TO CONSULTING CONTRACT

     THIS  AMENDMENT is made this ______ day of  ____________________,  2002, by
and between DNAPrint Genomics,  Inc., hereinafter "DNAPrint",  and Mark Shriver,
hereinafter "Consultant".

                                   BACKGROUND

     The parties hereto  entered into a consulting  contract dated June 12, 2002
and properly executed by the parties.

     The parties desire to make certain modifications to their contract.

     NOW, THERFORE,  in consideration of the mutual covenants  contained herein,
and intending to be legally bound, the parties agree as follows:

1.      The parties acknowledge that during the course of the development of
        projects by the parties either party may provide the other party with
        confidential and/or proprietary information. In order to protect said
        confidential and/or proprietary information, the parties have executed the
        confidentiality agreement attached hereto and marked Exhibit "A".

2.      DNAPrint has the right, pursuant to Section 1.1.4 of the Contract to modify
        consultants existing software programs. It is specifically understood that
        Consultant makes no warranties of any kind with respect to any software
        that has been modified or changed in any manner by DNAPrint. DNAPrint
        agrees to indemnify and hold Consultant harmless for any damages or losses
        arising as a result of such modifications or changes.

3.      Net sales as used in the Contract shall be defined as gross sales less
        returns, allowances, and sales discounts.

4.      The terms of the contract may apply to future projects to be developed by
        the parties. The parties agree that the terms of the original contract
        shall apply to any such additional projects. The parties further agree to
        execute a memorandum of the such additional projects which shall include
        the nature of the project and any changes to the original contract that may
        apply. Said projects shall include any project that consultant participates
        in its development.

5.      The parties agree that Section 2.2.2 shall be modified or clarified as
        follows:

                The net sales referred to shall refer to the net sales of DNAPrint and
                not the net sales of any particular license. The number of shares of
                restricted stock to be paid to Consultant shall be based on the price
                of the shares at the time of payment at the rate of 2.5% of sales.

                                       1

6.      Section 3.1 is modified by adding the following:

                The start date of the two (2) year term shall be the date when
                the Project starts. After the initial two (2) year term, either
                party may terminate the contract by giving at least sixty (60)
                days written notice prior to the end of any term.

7.      In all other respects the Agreement shall remain unchanged.

        Executed the date first above written.

WITNESS:

________________________                             _________________________
                                                     MARK SHRIVER

________________________                             _________________________
WITNESS:                                             DNAPRINT GENOMICS, INC.

________________________                         BY: _________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]